NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE.
Where this comes from
- Record sourced from PubMed, PMID 31263080.
- Also identified by DOI 10.2967/jnumed.118.230607 and PMC identifier 12079155.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
With the recent approval of <sup>177</sup>Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing. Representatives from the North American Neuroendocrine Tumor Society and the Society of Nuclear Medicine and Molecular Imaging collaborated to develop a practical consensus guideline for the administration of <sup>177</sup>Lu-DOTATATE. In this paper, we discuss patient screening, maintenance somatostatin analog therapy requirements, treatment location and room preparation, drug administration, and patient release as well as strategies for radiation safety, toxicity monitoring, management of potential complications, and follow-up. Controversies regarding the role of radiation dosimetry are discussed as well. This document is designed to provide practical guidance on how to safely treat patients with this therapy.
Medical subject headings
- Neuroendocrine Tumors
- Nuclear Medicine
- Octreotide
- Organometallic Compounds
- Receptors, Somatostatin
- Societies, Medical